DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Resiquimod is an investigational drug.
There have been 17 clinical trials for Resiquimod. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2005.
The most common disease conditions in clinical trials are Warts, Melanoma, and Influenza, Human. The leading clinical trial sponsors are Graceway Pharmaceuticals, LLC, Mayo Clinic, and National Cancer Institute (NCI).
Recent Clinical Trials for Resiquimod
|A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors||Ascendis Pharma Oncology Division A/S||Phase 1/Phase 2|
|A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients||Case Comprehensive Cancer Center||Phase 1/Phase 2|
|Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists||University of British Columbia||Phase 1|